TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06860516: HLA Demographics Study in Adults With Type 1 Diabetes

Sponsor: GentiBio, Inc · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06860516 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06860516 Rescue Dossier →